Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)
The global hemophilia market is anticipated to reach US$17.76 billion in 2028, growing at a CAGR of 5.81% during the period spanning 2024-2028. The growth in the market has been driven by factors like increasing healthcare expenditure, surging identified hemophilia patient volume, increased focus on prophylactic treatment, rise in male population and favorable government initiatives. The market is expected to face certain challenges such as high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like development of novel hemophilia treatments and rising popularity of gene therapy.
The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2023, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2023. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2023 was held by replacement therapy segment.
The global hemophilia market by region can be segmented into the following regions: North America, Europe and Asia Pacific. In 2023, the dominant share of the market was held by North America, followed by Europe and Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards growth in the North American market.
Scope of the report:
The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
The major regional markets North America, Europe and Asia Pacific with country analysis of the US have been analyzed.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.
Key Target Audience:
Hemophilia Drugs Manufacturers
API Suppliers
End Users (Hospital, Medical centers, Clinical Institutes)
Healthcare Consulting Firms
Investment Banks
Government Bodies & Regulating Authorities
1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
Table 1: Types of Hemophilia
1.3 Signs & Symptoms
Table 2: Signs & Symptoms of Hemophilia
1.4 Diagnosis of Hemophilia
Table 3: Diagnosis of Hemophilia
1.5 Treatment of Hemophilia
2. Impact of COVID-19
2.1 Impact on Global Economy
2.2 Global Prevalence of COVID-19
Table 4: Global Coronavirus Prevalence (May’21 – Dec’21)
2.3 Impact on Healthcare Spending
2.4 Post-COVID Scenario
3. Global Market Analysis
3.1 Global Hemophilia Market by Value
Table 5: Global Hemophilia Market by Value (2019-2023)
3.2 Global Hemophilia Market Forecast by Value
Table 6: Global Hemophilia Market Forecast by Value (2024-2028)
3.3 Global Hemophilia Market by Treatment Regimen
Table 7: Global Hemophilia Market by Treatment Regimen (2023)
3.4 Global Hemophilia Market by Type
Table 8: Global Hemophilia Market by Type (2023)
3.4.1 Global Hemophilia A Market Forecast by Value
Table 9: Global Hemophilia A Market Forecast by Value (2020-2028)
3.4.2 Global Hemophilia A Market by Severity
Table 10: Global Hemophilia A Market by Severity (2023)
3.4.3 Global Hemophilia A Market by Treatment Type
Table 11: Global Hemophilia A Market by Treatment Type (2023)
3.4.4 Global Hemophilia A Market by Treatment Regimen
Table 12: Global Hemophilia A Market by Treatment Regimen (2023 & 2028)
3.4.5 Global Hemophilia A Market Value by Treatment Regimen
Table 13: Global Hemophilia A Market Value by Treatment Regimen (2020-2028)
3.4.6 Global Hemophilia B Market Forecast by Value
Table 14: Global Hemophilia B Market Forecast by Value (2020-2028)
3.4.7 Global Hemophilia B Market by Severity
Table 15: Global Hemophilia B Market by Severity (2023)
3.4.8 Global Hemophilia B Market by Treatment Type
Table 16: Global Hemophilia B Market by Treatment Type (2023)
3.4.9 Global Hemophilia B Market by Treatment Regimen
Table 17: Global Hemophilia B Market by Treatment Regimen (2023 & 2028)
3.4.10 Global Hemophilia B Market Value by Treatment Regimen
Table 18: Global Hemophilia B Market Value by Treatment Regimen (2020-2028)
3.5 Global Hemophilia Market by Therapy
Table 19: Global Hemophilia Market by Therapy (2023)
3.5.1 Global Hemophilia Replacement Therapy Market Forecast by Value
Table 20: Global Hemophilia Replacement Therapy Market Forecast by Value (2020-2028)
3.5.2 Global Hemophilia ITI Therapy Market Forecast by Value
Table 21: Global Hemophilia ITI Therapy Market Forecast by Value (2020-2028)
3.6 Global Hemophilia Market by Region
Table 22: Global Hemophilia Market by Region (2023)
4. Regional Market Analysis
4.1 North America
4.1.1 North America Hemophilia Market by Value
Table 23: North America Hemophilia Market by Value (2019-2023)
4.1.2 North America Hemophilia Market Forecast by Value
Table 24: North America Hemophilia Market Forecast by Value (2024-2028)
4.1.3 The US Hemophilia Market by Value
Table 25: The US Hemophilia Market by Value (2019-2023)
4.1.4 The US Hemophilia Market Forecast by Value
Table 26: The US Hemophilia Market Forecast by Value (2024-2028)
4.1.5 The US Hemophilia Market by Type
Table 27: The US Hemophilia Market by Type (2023)
4.1.6 The US Hemophilia A Market Forecast by Value
Table 28: The US Hemophilia A Market Forecast by Value (2020-2028)
4.1.7 The US Hemophilia A Treated Patient Volume Forecast
Table 29: The US Hemophilia A Treated Patient Volume Forecast (2020-2028)
4.1.8 The US Hemophilia A Severe Patients on Prophylactic Therapy
Table 30: The US Hemophilia A Severe Patients on Prophylactic Therapy (2020-2028)
4.1.9 The US Hemophilia A Severe Patients on On-Demand Therapy
Table 31: The US Hemophilia A Severe Patients on On-Demand Therapy (2020-2028)
4.1.10 The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy
Table 32: The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy (2020-2028)
4.1.11 The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy
Table 33: The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy (2020-2028)
4.1.12 The US Hemophilia B Market Forecast by Value
Table 34: The US Hemophilia B Market Forecast by Value (2020-2028)
4.1.13 The US Hemophilia B Treated Patients Volume Forecast
Table 35: The US Hemophilia B Treated Patients Volume Forecast (2020-2028)
4.1.14 The US Hemophilia B Severe Patients on Prophylaxis Therapy
Table 36: The US Hemophilia B Severe Patients on Prophylaxis Therapy (2020-2028)
4.1.15 The US Hemophilia B Severe Patients on On-Demand Therapy
Table 37: The US Hemophilia B Severe Patients on On-Demand Therapy (2020-2028)
4.1.16 The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy
Table 38: The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy (2020-2028)
4.1.17 The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy
Table 39: The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy (2020-2028)
4.2 Europe
4.2.1 Europe Hemophilia Market by Value
Table 40: Europe Hemophilia Market by Value (2019-2023)
4.2.2 Europe Hemophilia Market Forecast by Value
Table 41: Europe Hemophilia Market Forecast by Value (2024-2028)
4.2.3 Europe Hemophilia Patient Volume Forecast
Table 42: Europe Hemophilia Patient Volume Forecast (2020-2028)
4.2.4 Europe Hemophilia A Patient Volume Forecast
Table 43: Europe Hemophilia A Patient Volume Forecast (2020-2028)
4.2.5 Europe Hemophilia B Patient Volume Forecast
Table 44: Europe Hemophilia B Patient Volume Forecast (2020-2028)
4.3 Asia Pacific
4.3.1 Asia Pacific Hemophilia Market by Value
Table 45: Asia Pacific Hemophilia Market by Value (2019-2023)
4.3.2 Asia Pacific Hemophilia Market Forecast by Value
Table 46: Asia Pacific Hemophilia Market Forecast by Value (2024-2028)
4.4 ROW
4.4.1 ROW Hemophilia Market by Value
Table 47: ROW Hemophilia Market by Value (2019-2023)
4.4.2 ROW Hemophilia Market Forecast by Value
Table 48: ROW Hemophilia Market Forecast by Value (2024-2028)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increased Focus on Prophylactic Treatment
Table 49: Global Market Share of Hemophilia A and B Patients on Prophylaxis (2019 & 2023)
5.1.2 Increasing Diagnosis Rate
Table 50: Global Identified Hemophilia Patients Volume (2019-2023)
5.1.3 Rise in Global Healthcare Expenditure
Table 51: Global Health Spending Per Capita (2018-2023)
5.1.4 Rise in Male Population
Table 52: Global Male Population (2016-2023)
5.1.5 Favourable Government Initiatives
5.2 Key Trends & Development
5.2.1 Shifting Focus to Extended Half Life Therapies
Table 53: Extended Half Life Products
5.2.2 Development of Novel Hemophilia Treatments
Table 54: Development of New Novel Hemophilia Treatments
5.2.3 Popularity of Gene Therapy
Table 55: Hemophilia Gene Therapy Candidates
5.3 Challenges
5.3.1 High Cost of Treatment
5.3.2 Reluctance to Switch to New Therapies
6. Competitive Landscape
6.1 Global Market
6.1.1 Global Hemophilia A Market Share by Company
Table 56: Global Hemophilia A Market Share by Company (2023)
6.1.2 Global Hemophilia A Factor VIII Products Market Share by Company
Table 57: Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
6.1.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
Table 58: Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
6.1.4 Global Hemophilia B Market Share by Company
Table 59: Global Hemophilia B Market Share by Company (2023)
6.1.5 Global Hemophilia B Factor IX Products Market Share Forecast
Table 60: Global Hemophilia B Factor IX Products Market Share Forecast (2023/2030)
6.1.6 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
Table 61: Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
6.2 The US Market
6.2.1 The US Hemophilia A Market Share by Company
Table 62: The US Hemophilia A Market Share by Company (2023)
6.3 Europe Market
6.3.1 Europe Hemophilia A Market Share by Company
Table 63: Europe Hemophilia B Market Share by Company (2023)